ASH 2020: Novel CAR-T Approaches Chase BCMA-Targeting Frontrunners
New Poseida Manufacturing Boosts Efficacy; Allogene Has First Allogeneic
BMS/bluebird and Janssen/Legend have the leading BCMA-targeting CAR-T therapies for multiple myeloma but Poseida, Allogene, CARsgen, Gracell and CBMG are emerging with novel approaches.
